CIK 0001812364 · Large accelerated filer
Relay Therapeutics, Inc.
Sign in to watch- Ticker
- RLAY
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-370-8837
- Business address
- 60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Open-market sale President and CEO sold 42,000 shares at an average $20.99 ($881,720)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale See remarks sold 740 shares at $21.56 ($15,954)
- 5 Insider Annual Insider Trading Report
- 4 Open-market sale Chief Financial Officer sold 864 shares at $21.56 ($18,628)
- 4 Open-market sale President, R&D sold 1,429 shares at $21.56 ($30,809)
- 4 Open-market sale Chief Legal Officer sold 864 shares at $21.56 ($18,628)
- 4 Grant or award See remarks acquired 97,630 shares (grant or award)
- 4 Open-market sale President and CEO sold 84,000 shares at an average $20.37 ($1,711,360)
- 4 Grant or award Chief Financial Officer acquired 101,115 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 85,425 shares (grant or award)
- 4 Grant or award President, R&D acquired 160,390 shares (grant or award)
- 4 Open-market sale Chief Legal Officer sold 9,994 shares at $20.00 ($199,880)
- 8-K Event Regulation FD disclosure
Page 17 of 28 · 556 filings